The GTF2I rs117026326 polymorphism is associated with anti-SSA-positive primary Sjögren's syndrome.

Junfeng Zheng,Renliang Huang,Qiaoniang Huang,Fengyuan Deng,Yan Chen,Junping Yin,Juan Chen,Ying Wang,Guixiu Shi,Xing Gao,Zuguo Liu,Frank Petersen,Xinhua Yu
DOI: https://doi.org/10.1093/rheumatology/keu466
2014-01-01
Abstract:Disclosure statement: S.G.M. has received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Bayer, Biogen Idec, Sanofi-Aventis, Bayer Schering, Merck Serono, Novo Nordisk, Genzyme, MSD and Teva. T.R. has received travel expenses and financial research support from Genzyme and has received honoraria for lecturing from Teva and Biogen Idec. H.W. has received compensation for serving on scientific advisory boards/steering committees for Bayer Healthcare, Biogen Idec, Genzyme, Merck Serono, Novartis and Sanofi Aventis; has received speaker’s honoraria and travel support from Bayer Vital, Bayer Schering, Biogen Idec, CSL Behring, Fresenius Medical Care, Genzyme, GlaxoSmithKline, GW Pharmaceuticals, Lundbeck, Merck Serono, Omniamed, Novartis and Sanofi Aventis; has received compensation as a consultant from Biogen Idec, Merck Serono, Novartis and Sanofi Aventis and has received research support from Bayer Vital, Biogen Idec, Genzyme Merck Serono, Novartis, Sanofi Aventis Germany and Sanofi US. S.B. has received financial research support from Novartis and has received honoraria for lecturing from Biogen Idec and Teva. The other author has declared no conflicts of interest.
What problem does this paper attempt to address?